Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 241,250,093 papers from all fields of science
Search
Sign In
Create Free Account
ZD 1839
Known as:
ZD1839
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
gefitinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The GSK-3β/Cyclin D1 Pathway is Involved in the Resistance of Oral Cancer Cells to the EGFR Tyrosine Kinase Inhibitor ZD1839
Nam Kyeong Jeon
,
Jin Kim
,
Eun Ju Lee
2014
Corpus ID: 94586841
Activation of the epidermal growth factor receptor (EGFR) and downstream signaling pathways have been implicated in causing…
Expand
2007
2007
Terapias con inhibidores del receptor del factor de crecimiento epidérmico: acercando el futuro
A. Moreno Díaz
,
A. Lage
2007
Corpus ID: 29443641
La funcion esencial del receptor del factor de crecimiento epidermico (REGF) en diversos tipos de tumores solidos lo ha…
Expand
Review
2005
Review
2005
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors : Tissue Analysis fromNorth
A. Lassman
,
M. Rossi
,
+17 authors
E. Holland
2005
Corpus ID: 41992762
Purpose:We investigated the molecular effect of the epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib in…
Expand
2004
2004
Gefitinib ( ZD 1839 ) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
Jinny Park
,
B. Park
,
+14 authors
Keunchil Park
2004
Corpus ID: 11626988
Purpose: A worldwide compassionate-use program has enabled >42,000 patients with advanced non-small cell lung cancer (NSCLC) to…
Expand
2004
2004
Community practice experience with gefitinib (ZD1839) as treatment for patients with advanced non-small-cell lung cancer (NSCLC) within an expanded access clinical program
T. Ervin
,
S. Toothaker
2004
Corpus ID: 201949430
7367 Background: Preclinical and clinical studies including IDEAL 1 and 2 showed that oral gefitinib (Iressa, ZD1839) is an…
Expand
2003
2003
Efficacy and safety of gefitinib (Iressa, ZD1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small cell lung cancer
M. Kris
,
R. Natale
,
+12 authors
A. Kay
2003
Corpus ID: 90646089
Review
2003
Review
2003
Recent Advances with Molecular Target Agents in Cancer: Opportunities for Imaging
J. Dancey
2003
Corpus ID: 70397751
A number of agents targeting components of pathways and processes critical to neoplastic transformation and progression are…
Expand
2001
2001
Combination of ZD1839 ("Iressa"), an EGFR-TKI, and radiotherapy increases anti-tumour efficacy in a human colon cancer xenograft model
K. Williams
,
B. Telfer
,
I. Stratford
,
S. Wedge
2001
Corpus ID: 78392337
2001
2001
ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]
R. Nicholson
,
M. Harper
,
+6 authors
J. Gee
2001
Corpus ID: 70557032
2000
2000
ZD1839 (Iressa (TM)), an EGFR-TKI, and cisplatin have an additive effect on programmed cell death in human head and neck squamous carcinoma cells in vitro.
A. Al-Haza'a
,
M. Birchall
,
I. Bowen
2000
Corpus ID: 78386843